Tyme Technologies Inc (TYME):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Tyme Technologies Inc (TYME) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9370
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Tyme Technologies Inc (Tyme) is a clinical-stage pharmaceutical company. The company focused on discovering and developing targeted cancer therapeutics for oncology indications. It develops clinical program SM-88, an oral tyrosine-based therapy that is currently in Phase II development for prostate cancer. Tyme develops SM-88, a combination therapy utilizing proprietary dysfunctional tyrosine derivative as the backbone. The company offers SM-88 tyrosine derivative, which is designed to be absorbed by cancer cell as if it were a functional tyrosine, but after uptake, interrupt metabolic processes like protein synthesis. The company’s therapeutic intervention is designed to compromise cancer’s cellular defences and exploits its innate metabolic weaknesses, which leads to cell death through oxidative stress and exposing cancer to the body’s natural immune system. Tyme is headquartered in New York, the US.

Tyme Technologies Inc (TYME) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tyme Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Tyme Technologies Enters into Collaboration Agreement with Joseph Ahmed 11
Tyme Technologies Enters into Co-development Agreement with University of California San Francisco 12
Merger 13
Tyme Technologies Merges with Tyme in Reverse Merger Transaction 13
Equity Offering 14
Tyme Technologies Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD23.3 Million 14
Tyme Technologies Raises USD8.2 Million in Private Placement of Shares and Warrants 16
Tyme Technologies Files Shelf Registration with SEC To Raise USD250 Million 17
Tyme Technologies Raises USD3.1 Million in Private Placement of Shares 18
Tyme Technologies Raises USD7 Million in Private Placement of Common Stock 19
Tyme Technologies Inc – Key Competitors 20
Tyme Technologies Inc – Key Employees 21
Tyme Technologies Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Jul 30, 2018: Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019 23
Corporate Communications 25
Oct 15, 2018: Tyme Technologies names Michele Korfin as Chief Commercial Officer 25
Sep 18, 2018: Tyme Technologies names Douglas A. Michels as Board Director 26
Feb 21, 2018: Tyme Technologies Appoints Tommy G. Thompson to Board of Directors 27
Sep 14, 2017: Tyme Adds Distinguished Drug Developer, Briggs W. Morrison, M.D. to Advisory Board 28
Aug 09, 2017: Tyme Appoints Dr. Jonathan Eckard as Chief Scientific Affairs Officer 29
Mar 29, 2017: Tyme Technologies Announces Two New Board of Director Appointments — David Carberry and James Biehl 30
Mar 23, 2017: Tyme Appoints Ben Taylor as President and Chief Financial Officer 31
Mar 02, 2017: Tyme Technologies Appoints Healthcare Veteran Paul L. Sturman as Independent Director 32
Product News 33
06/05/2017: Tyme Technologies Presents Positive Interim Clinical Data in Recurrent, Non-Metastatic Prostate Cancer at ASCO 2017 33
05/22/2017: Tyme Technologies to Present New Clinical Data for Investigational Drug Candidate SM-88 at 2017 ASCO Annual Meeting 34
01/06/2017: Tyme Technologies Announces Hiring of Shabnam Stanicky as Clinical Operations Officer 35
01/05/2017: Tyme Technologies Advances SM-88 into the Second Stage of its Phase Ib/II Prostate Cancer Trial 36
Other Significant Developments 37
Nov 05, 2018: Tyme provides clinical and corporate update for fiscal 2Q 2019 37
Apr 09, 2018: Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018 38
Feb 07, 2018: Tyme Provides Clinical and Corporate Update for Fiscal Third Quarter 2017 39
Nov 08, 2017: Tyme Provides Clinical and Corporate Update for the Fiscal First Half 2017 40
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tyme Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tyme Technologies Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tyme Technologies Enters into Collaboration Agreement with Joseph Ahmed 11
Tyme Technologies Enters into Co-development Agreement with University of California San Francisco 12
Tyme Technologies Merges with Tyme in Reverse Merger Transaction 13
Tyme Technologies Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD23.3 Million 14
Tyme Technologies Raises USD8.2 Million in Private Placement of Shares and Warrants 16
Tyme Technologies Files Shelf Registration with SEC To Raise USD250 Million 17
Tyme Technologies Raises USD3.1 Million in Private Placement of Shares 18
Tyme Technologies Raises USD7 Million in Private Placement of Common Stock 19
Tyme Technologies Inc, Key Competitors 20
Tyme Technologies Inc, Key Employees 21

List of Figures
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tyme Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Tyme Technologies Inc (TYME):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TAP Biosystems Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary TAP Biosystems Ltd (TAP), a subsidiary of Sartorius Stedim Biotech GmbH is a provider of laboratory and pharmaceutical equipment. The company designs and manufactures automated cell culture, bio-reactor systems and fermentation systems. It also provides labware, consumables and accessories. …
  • eNeura Inc-医療機器分野:企業M&A・提携分析
    Summary eNeura Inc (eNeura) formerly eNeura Therapeutics LLC, is a medical device company that offers portable, non-invasive transcranial magnetic stimulation devices for treating migraine. The company offers products such as flagship product and eNeura Spring TMS device. Its SpringTMS device is pla …
  • Tribune Media Co:企業の戦略的SWOT分析
    Tribune Media Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • MegaChips Corp (6875):企業の財務・戦略的SWOT分析
    MegaChips Corp (6875) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Hotel Royal Limited:戦略・SWOT・企業財務分析
    Hotel Royal Limited - Strategy, SWOT and Corporate Finance Report Summary Hotel Royal Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Santander UK PLC:企業の戦略・SWOT・財務分析
    Santander UK PLC - Strategy, SWOT and Corporate Finance Report Summary Santander UK PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Resona Holdings, Inc.:企業の戦略・SWOT・財務情報
    Resona Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Resona Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Apollo Education Group Inc:企業の戦略的SWOT分析
    Apollo Education Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Nielsen Holdings PLC:企業の戦略・SWOT・財務情報
    Nielsen Holdings PLC - Strategy, SWOT and Corporate Finance Report Summary Nielsen Holdings PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Pernix Therapeutics Holdings Inc (PTX):企業の財務・戦略的SWOT分析
    Pernix Therapeutics Holdings Inc (PTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Centerra Gold Inc.
    Centerra Gold Inc. - Strategy, SWOT and Corporate Finance Report Summary Centerra Gold Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Elektrani na Makedonija:企業の戦略的SWOT分析
    Elektrani na Makedonija - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Toei Animation Co., Ltd. (4816):企業の財務・戦略的SWOT分析
    Toei Animation Co., Ltd. (4816) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Edan Instruments Inc (300206):企業の財務・戦略的SWOT分析
    Summary Edan Instruments Inc (Edan Instruments) is a medical equipment provider that offers ECG equipments. The company offers diagnostic ECG, obstetrics and gynaecology monitoring systems; patient monitoring devices, ultrasound imaging, point-of-care testing, in-vitro diagnostics and veterinary equ …
  • Delta International Oil & Gas Inc (DLTZ):石油・ガス:M&Aディール及び事業提携情報
    Summary Delta International Oil & Gas Inc (Delta), formerly Delta Mutual Inc, is an oil and gas company. The company operates in the oil and gas acquisition and exploration activities. It also holds interests in oil and natural gas and development rights in Argentina. Delta’s oil and gas investments …
  • Air Liquide SA (AI):医療機器:M&Aディール及び事業提携情報
    Summary Air Liquide SA (Air Liquide) is a provider of gases, technologies and services for industrial and health care sectors. The company produces core air gases such as oxygen, nitrogen, and hydrogen along with argon and other rare gases. It supplies gases to customers in industries, including ste …
  • Welltower Inc:企業のM&A・事業提携・投資動向
    Welltower Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Welltower Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • JGC Holdings Corp (1963)
    JGC Holdings Corp (1963) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Pt Bakrieland Development Tbk:企業の戦略・SWOT・財務分析
    Pt Bakrieland Development Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Bakrieland Development Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Alimera Sciences Inc (ALIM):医療機器:M&Aディール及び事業提携情報
    Summary Alimera Sciences Inc (Alimera) is a biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. The company’s products include Iluvien, an intravitreal implant of fluocinolone acetonide which is indicated for the treatment of chronic diabet …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆